Carolina N Susanna1, Alberto Diniz-Filho2, Fábio B Daga3, Bianca N Susanna1, Feilin Zhu2, Nara G Ogata3, Felipe A Medeiros4. 1. Duke Eye Center and Department of Ophthalmology, Duke University, Durham, North Carolina; Department of Ophthalmology, University of California San Diego, La Jolla, California. 2. Department of Ophthalmology, University of California San Diego, La Jolla, California. 3. Duke Eye Center and Department of Ophthalmology, Duke University, Durham, North Carolina. 4. Duke Eye Center and Department of Ophthalmology, Duke University, Durham, North Carolina; Department of Ophthalmology, University of California San Diego, La Jolla, California. Electronic address: felipe.medeiros@duke.edu.
Abstract
PURPOSE: To investigate the role of corneal hysteresis (CH) as a risk factor for development of glaucoma. DESIGN: Prospective observational cohort study. METHODS: Two hundred and eighty-seven eyes of 199 patients suspected of having glaucoma were followed for an average of 3.9 ± 1.8 years. All eyes had normal visual fields at baseline. Development of glaucoma was defined as occurrence of 3 consecutive abnormal standard automated perimetry tests during follow-up, defined as pattern standard deviation (PSD) < 5%, and/or Glaucoma Hemifield Test outside normal limits. Measurements of CH were acquired at baseline using the Ocular Response Analyzer (ORA). Univariable and multivariable Cox regression models were used to investigate baseline factors associated with development of visual field loss over time. RESULTS: Fifty-four (19%) eyes developed repeatable visual field defects during follow-up. Measurements of CH at baseline were significantly lower in patients who developed glaucoma vs those who did not (9.5 ± 1.5 mm Hg vs 10.2 ± 2.0 mm Hg; P = .012). Each 1-mm Hg lower CH was associated with an increase of 21% in the risk of developing glaucoma during follow-up (95% confidence interval [CI]: 1.04-1.41; P = .013). In a multivariable model adjusting for age, intraocular pressure, central corneal thickness, PSD, and treatment, CH was still predictive of development of glaucoma (hazard ratio = 1.20; 95% CI: 1.01-1.42; P = .040). CONCLUSION: Baseline lower CH measurements were significantly associated with increased risk of developing glaucomatous visual field defects over time. The prospective longitudinal design of this study supports a role of CH as a risk factor for developing glaucoma.
PURPOSE: To investigate the role of corneal hysteresis (CH) as a risk factor for development of glaucoma. DESIGN: Prospective observational cohort study. METHODS: Two hundred and eighty-seven eyes of 199 patients suspected of having glaucoma were followed for an average of 3.9 ± 1.8 years. All eyes had normal visual fields at baseline. Development of glaucoma was defined as occurrence of 3 consecutive abnormal standard automated perimetry tests during follow-up, defined as pattern standard deviation (PSD) < 5%, and/or Glaucoma Hemifield Test outside normal limits. Measurements of CH were acquired at baseline using the Ocular Response Analyzer (ORA). Univariable and multivariable Cox regression models were used to investigate baseline factors associated with development of visual field loss over time. RESULTS: Fifty-four (19%) eyes developed repeatable visual field defects during follow-up. Measurements of CH at baseline were significantly lower in patients who developed glaucoma vs those who did not (9.5 ± 1.5 mm Hg vs 10.2 ± 2.0 mm Hg; P = .012). Each 1-mm Hg lower CH was associated with an increase of 21% in the risk of developing glaucoma during follow-up (95% confidence interval [CI]: 1.04-1.41; P = .013). In a multivariable model adjusting for age, intraocular pressure, central corneal thickness, PSD, and treatment, CH was still predictive of development of glaucoma (hazard ratio = 1.20; 95% CI: 1.01-1.42; P = .040). CONCLUSION: Baseline lower CH measurements were significantly associated with increased risk of developing glaucomatous visual field defects over time. The prospective longitudinal design of this study supports a role of CH as a risk factor for developing glaucoma.
Authors: Maziar Lalezary; Felipe A Medeiros; Robert N Weinreb; Christopher Bowd; Pamela A Sample; Ivan M Tavares; Ali Tafreshi; Linda M Zangwill Journal: Am J Ophthalmol Date: 2006-10 Impact factor: 5.258
Authors: Aashish Anand; Carlos Gustavo V De Moraes; Christopher C Teng; Celso Tello; Jeffrey M Liebmann; Robert Ritch Journal: Invest Ophthalmol Vis Sci Date: 2010-06-23 Impact factor: 4.799
Authors: Felipe A Medeiros; Pamela A Sample; Linda M Zangwill; Christopher Bowd; Makoto Aihara; Robert N Weinreb Journal: Am J Ophthalmol Date: 2003-11 Impact factor: 5.258
Authors: Michael Sullivan-Mee; Shavon C Billingsley; Amita D Patel; Kathy D Halverson; Brooks R Alldredge; Clifford Qualls Journal: Optom Vis Sci Date: 2008-06 Impact factor: 1.973
Authors: C Starck Johnson; Shahzad I Mian; Sayoko Moroi; David Epstein; Joseph Izatt; Natalie A Afshari Journal: Invest Ophthalmol Vis Sci Date: 2007-06 Impact factor: 4.799
Authors: Felipe A Medeiros; Daniel Meira-Freitas; Renato Lisboa; Tung-Mei Kuang; Linda M Zangwill; Robert N Weinreb Journal: Ophthalmology Date: 2013-05-01 Impact factor: 12.079
Authors: Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill; Luciana M Alencar; Pamela A Sample; Cristiana Vasile; Christopher Bowd Journal: Ophthalmology Date: 2007-10-15 Impact factor: 12.079
Authors: Brandon J Wong; Sasan Moghimi; Linda M Zangwill; Mark Christopher; Akram Belghith; Eren Ekici; Christopher Bowd; Massimo A Fazio; Christopher A Girkin; Robert N Weinreb Journal: Am J Ophthalmol Date: 2019-11-23 Impact factor: 5.258